Literature DB >> 19606019

Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M.

Sebastian Knauer1, Bernhard Biersack, Miroslava Zoldakova, Katharina Effenberger, Wolfgang Milius, Rainer Schobert.   

Abstract

The unfavorable therapeutic index of the fungal cytotoxin illudin M was to be improved by covalent attachment of the redox modulator and phenyl isobiostere ferrocene. Esters of illudin M with ferrocenoic and 1,1'-ferrocenedioic acid were prepared, structurally characterised (X-ray), and tested for cytotoxicity [MTT assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], induction of apoptosis (TUNEL assay; western blotting for caspase-9), and tumor specificity in cells of human HL-60 leukemia, human 518A2 melanoma, and in nonmalignant human foreskin fibroblasts. The diester of illudin M with 1,1'-ferrocenedioic acid was distinctly more antiproliferative and apoptosis inducing in the melanoma cells [half maximal inhibitory concentration, IC50(48 h) = 0.4+/-0.1 micromol/l] than in the HL-60 cells [IC50(48 h) = 3.0+/-1.6 micromol/l] and in the nonmalignant fibroblasts [IC50(48 h) = 3.7+/-1.9 micromol/l]. This corresponds to a doubling of the therapeutic index with respect to illudin M. The monoester of illudin M with ferrocenoic acid was nine times less efficacious in the cancer cells, when compared with the diester. In conclusion, the ferrocene diminishes the general toxicity of the illudin M moiety and increases its cell line specificity. The bis(illudinyl M) 1,1'-ferrocenedioate presumably operates by a synergistic, two-pronged attack on its molecular targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19606019     DOI: 10.1097/CAD.0b013e32832e056a

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  Optimization of the production process for the anticancer lead compound illudin M: process development in stirred tank bioreactors.

Authors:  Lillibeth Chaverra-Muñoz; Stephan Hüttel
Journal:  Microb Cell Fact       Date:  2022-07-18       Impact factor: 6.352

2.  Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks.

Authors:  Lillibeth Chaverra-Muñoz; Theresa Briem; Stephan Hüttel
Journal:  Microb Cell Fact       Date:  2022-05-28       Impact factor: 6.352

3.  Optimization of the production process for the anticancer lead compound illudin M: downstream processing.

Authors:  Lillibeth Chaverra-Muñoz; Theresa Briem; Stephan Hüttel
Journal:  Microb Cell Fact       Date:  2022-08-17       Impact factor: 6.352

4.  Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.

Authors:  Malgorzata Sztiller-Sikorska; Kamila Koprowska; Kinga Majchrzak; Mariusz Hartman; Malgorzata Czyz
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.